Table of Contents Table of Contents
Previous Page  41 / 42 Next Page
Information
Show Menu
Previous Page 41 / 42 Next Page
Page Background

Some take home messages

• Monotherapy is the standard today in PD-L1>50%.

• Combinations must be better than monotherapy but not for all.

• Multiple remaining questions—?

• We need betters biomarkers.

• Different toxicities and more toxic in combo!!.

• Several phase 3 IO-CT and IO-IO now ongoing but close.